Subtopic Deep Dive
ACVR1 Mutations in Fibrodysplasia Ossificans Progressiva
Research Guide
What is ACVR1 Mutations in Fibrodysplasia Ossificans Progressiva?
ACVR1 mutations in fibrodysplasia ossificans progressiva (FOP) are gain-of-function variants in the BMP type I receptor causing ectopic bone formation in soft tissues.
The canonical R206H mutation in ACVR1 drives FOP by conferring responsiveness to activin A (Hatsell et al., 2015, 430 citations). These mutations occur in ~95% of cases, with atypical variants linked to variable phenotypes (Kaplan et al., 2008, 434 citations). Over 20 papers detail genotype-phenotype correlations and mosaicism since Shore et al.'s 2006 discovery (1198 citations).
Why It Matters
ACVR1 R206H mutations enable precision therapies targeting activin A signaling, as shown in patient-derived models (Hatsell et al., 2015). Understanding sporadic vs. inherited cases informs genetic counseling and trial eligibility (Shore et al., 2006). FOP research advances broader heterotopic ossification treatments post-trauma (Yu et al., 2008; Meyers et al., 2019).
Key Research Challenges
Genotype-Phenotype Variability
Atypical ACVR1 mutations produce milder FOP phenotypes, complicating diagnosis (Kaplan et al., 2008). Mosaicism in sporadic cases challenges mutation detection sensitivity. Over 15 variants reported require functional assays for classification.
Activin A Receptor Switching
R206H mutation shifts ACVR1 from activin inhibition to activation, driving ossification (Hatsell et al., 2015). Ligand-specific signaling demands targeted inhibitors over broad BMP blockers. Mouse models replicate but underestimate human flare-ups.
Therapy Resistance Mechanisms
BMP pathway inhibitors reduce heterotopic ossification experimentally but face FOP-specific activin bypass (Yu et al., 2008). Somatic mosaicism may limit systemic drug efficacy. Clinical trials need biomarkers beyond ACVR1 sequencing.
Essential Papers
TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease
Mengrui Wu, Guiqian Chen, Yiping Li · 2016 · Bone Research · 1.5K citations
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva
Eileen M. Shore, Meiqi Xu, George Feldman et al. · 2006 · Nature Genetics · 1.2K citations
BMP type I receptor inhibition reduces heterotopic ossification
Paul B. Yu, Donna Y. Deng, Carol Lai et al. · 2008 · Nature Medicine · 612 citations
TGF-β/BMP signaling and other molecular events: regulation of osteoblastogenesis and bone formation
Md Shaifur Rahman, Naznin Akhtar, Hossen Mohammad Jamil et al. · 2015 · Bone Research · 555 citations
Transforming growth factor-beta (TGF-β)/bone morphogenetic protein (BMP) plays a fundamental role in the regulation of bone organogenesis through the activation of receptor serine/threonine kinases...
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
Kathryn R. Taylor, Alan Mackay, Nathalène Truffaux et al. · 2014 · Nature Genetics · 513 citations
Bone Morphogenetic Proteins
Takenobu Katagiri, Tetsuro Watabe · 2016 · Cold Spring Harbor Perspectives in Biology · 493 citations
Bone morphogenetic proteins (BMPs), originally identified as osteoinductive components in extracts derived from bone, are now known to play important roles in a wide array of processes during forma...
Heterotopic Ossification: A Comprehensive Review
Carolyn A. Meyers, Jeffrey Lisiecki, Sarah Miller et al. · 2019 · JBMR Plus · 456 citations
ABSTRACT Heterotopic ossification (HO) is a diverse pathologic process, defined as the formation of extraskeletal bone in muscle and soft tissues. HO can be conceptualized as a tissue repair proces...
Reading Guide
Foundational Papers
Read Shore et al. (2006, 1198 citations) first for mutation discovery, then Kaplan et al. (2008, 434 citations) for classic/atypical phenotypes.
Recent Advances
Study Hatsell et al. (2015, 430 citations) for activin A mechanism; Meyers et al. (2019, 456 citations) contextualizes in heterotopic ossification.
Core Methods
Sequencing for variants (Shore 2006); ligand-receptor binding assays (Hatsell 2015); BMP inhibitor models (Yu 2008).
How PapersFlow Helps You Research ACVR1 Mutations in Fibrodysplasia Ossificans Progressiva
Discover & Search
Research Agent uses searchPapers('ACVR1 R206H FOP mutations') to retrieve Shore et al. (2006, 1198 citations), then citationGraph reveals 200+ citing papers on variants, and findSimilarPapers expands to Hatsell et al. (2015) for activin mechanisms.
Analyze & Verify
Analysis Agent applies readPaperContent on Hatsell et al. (2015) to extract activin A signaling data, verifyResponse with CoVe cross-checks R206H functionality against Kaplan et al. (2008), and runPythonAnalysis plots mutation frequencies from 10 papers using pandas for statistical verification; GRADE scores evidence as high for causal role.
Synthesize & Write
Synthesis Agent detects gaps in atypical variant therapies via contradiction flagging between Shore (2006) and Kaplan (2008), then Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates 15 references, and latexCompile generates a review PDF with exportMermaid diagrams of BMP/ACVR1 pathways.
Use Cases
"Extract mutation frequencies from FOP patient cohorts across 10 papers and plot distribution."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas aggregation of Shore 2006, Kaplan 2008 cohorts) → matplotlib bar chart of R206H vs. atypical variants prevalence.
"Write LaTeX review section on ACVR1 activin responsiveness with citations and pathway figure."
Synthesis Agent → gap detection → Writing Agent → latexEditText('activin A section') → latexSyncCitations(Shore 2006, Hatsell 2015) → latexCompile → exportMermaid(BMP signaling diagram).
"Find GitHub repos with ACVR1 FOP simulation code from recent papers."
Research Agent → paperExtractUrls(Hatsell 2015) → paperFindGithubRepo → Code Discovery → githubRepoInspect → verified simulation scripts for mutant receptor modeling.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ ACVR1 papers: searchPapers → citationGraph → DeepScan 7-step analysis with GRADE checkpoints on mutation causality. Theorizer generates hypotheses on mosaicism-therapy interactions from Shore (2006) and Kaplan (2008), outputting testable models. DeepScan verifies activin claims across Hatsell (2015) and Yu (2008) via CoVe chains.
Frequently Asked Questions
What defines ACVR1 mutations in FOP?
Gain-of-function mutations, primarily R206H, in the BMP type I receptor ACVR1 cause FOP by enabling ectopic ossification (Shore et al., 2006).
What are key methods for studying these mutations?
Functional assays show R206H confers activin A responsiveness (Hatsell et al., 2015); sequencing detects mosaicism in sporadic cases (Kaplan et al., 2008).
What are the most cited papers?
Shore et al. (2006, 1198 citations) identified the recurrent mutation; Hatsell et al. (2015, 430 citations) explained activin mechanism.
What open problems remain?
Atypical variants' incomplete penetrance needs functional classification; somatic mosaicism limits therapies (Kaplan et al., 2008).
Research Heterotopic Ossification and Related Conditions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching ACVR1 Mutations in Fibrodysplasia Ossificans Progressiva with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers